Research in contextEvidence before this studyThe underlying mechanisms of 50% of cases with recurrent pregnancy loss (RPL) are unknown, it is an emerging area of interest to identify the risk factors contributing to RPL. We searched PubMed with the terms "recurrent pregnancy loss" and "DNA methylation" for original research articles up to March 1, 2016. There were no language restrictions. In these studies, DNA methylation was measured at either global level or small set of genes on the basis of existing hypotheses. Few studies focused on the genome wide DNA methylation and the regulatory role of DNA methylation on gene expression in RPL.Added value of this studyIn the present study, we identified *CREB5* as a novel risk gene contributing to recurrent pregnancy loss by performing genome-wide DNA methylation analysis combined with RNA-seq analysis in decidua tissue. In mechanism, hypomethylation of *CREB5* upregulated its expression and caused dysfunction of trophoblast cells, which might contribute to RPL.Implications of all the available evidenceTo our knowledge, this is the first study to explore the alternations of decidua DNA methylome on gene regulations in RPL. Our research provides new insights into *CREB5* dependent regulatory effects during RPL and suggests DNA methylation of *CREB5* may be a potential biomarker for RPL diagnosis.Alt-text: Unlabelled Box

1. Introduction {#s0020}
===============

Recurrent pregnancy loss (RPL), defined as the failure of two or more consecutive clinical pregnancies before 20 weeks of gestation, affects approximately 1% of couples attempting to conceive \[[@bb0005]\]. The known causes of RPL include chromosomal abnormalities, maternal reproductive tract abnormalities, maternal endocrine abnormalities, immune dysfunction, genital tract infections, cervical insufficiency and environmental exposures \[[@bb0010]\]. However, the underlying mechanisms of 50% of cases are unknown \[[@bb0015]\].

The placenta plays a crucial role during pregnancy, which allows oxygen exchange, nutrients uptake and waste removal. The maternal portion of the placenta is known as the decidua, which can provide a delicate balance between immune tolerance and defense to maintain the pregnancy \[[@bb0020]\]. During early pregnancy, failure of cell invasion, immune tolerance and arterial remodeling in the developing decidua, which are controlled by complicated epigenetic modification network, may lead to poor implantation, inflammation and impaired placental development \[[@bb0025]\].

DNA methylation, one of major epigenetic modifications, plays important roles in the regulation of gene expression, X-inactivation, genomic imprinting, genome stabilization and chromatin modification, which are crucial for normal embryonic development \[[@bb0030], [@bb0035], [@bb0040]\]. During the early stages of embryogenesis, extensive epigenetic modifications occur, and the total demethylation phase alternates with the remethylation phase to ensure the pluripotency of the developing embryo \[[@bb0045]\]. However, some parental epigenetic modifications may escape the second wave of demethylation, indicating a potential inheritance of epigenetic modifications set during gametogenesis \[[@bb0050], [@bb0055]\]. Aberrant DNA methylation has been reported to be involved in human miscarriage, pre-eclampsia, abnormal embryonic development and birth malformations \[[@bb0060], [@bb0065], [@bb0070], [@bb0075]\]. Epigenetic mechanism in early life altered function and structure of organs, which played an important role for diseases in later life \[[@bb0080]\]. It has been shown that abnormal DNA methylation in the chorionic villus, especially at the loci of the imprinting genes, resulted in RPL in patients with normal karyotype \[[@bb0085], [@bb0090]\]. In addition, epigenetic alterations in placenta have been reported to be associated with gestational diabetes mellitus and hypertension, which are also involved in pregnancy loss \[[@bb0095], [@bb0100]\]. Moreover, hyper-methylation at the promoter of *FOXP3*, which is indispensable for the differentiation of Treg cells, led to down-regulate *FOXP3* and broke the immune balance in maternal-fetal interface \[[@bb0105]\]. Several studies suggested that abnormal methylation existed in semen samples from couples with RPL \[[@bb0110], [@bb0115]\]. However, most of these studies only measured small set of genes on the basis of existing hypotheses about the etiology of RPL, which might bias interpretation. Additionally, few studies reported the DNA methylation level of decidua and clarified the contribution of decidua methylation change on gene regulations involved in RPL.

Thus, we assessed alterations in DNA methylation by Infinium Human Methylation 850 K BeadChips and gene expression by RNA-sequencing analysis (RNA-seq) in decidua samples from RPL patients and controls with induced abortions. Eventually, *CREB5* gene (cAMP responsive element binding protein 5), up-regulation in RPL through hypo-methylation in promoters, was found to compromise the trophoblast cellular functions, which might in turn lead to RPL.

2. Materials and methods {#s0025}
========================

2.1. Ethics statement {#s0030}
---------------------

This study was approved by the Institutional Ethics Committee of Nanjing Medical University. All experiment protocols were approved by the Institutional Review Board of Nanjing Medical University prior to the study. All activities involved in this study were done under full compliance with government policies and the Helsinki Declaration.

2.2. Study population and sample collection {#s0035}
-------------------------------------------

20 normal pregnant women (non-medical reasons for abortion) and 80 RPL patients were recruited from the affiliated hospitals of Nanjing Medical University between 2012 and 2015. A questionnaire was used to collect recruited couples\' characteristic information including personal information, lifestyle factors and medical history. Females with infection, endocrine abnormalities, antiphospholipid syndrome or other known risk factors for RPL were excluded from the study. Through array-based Comparative Genomic Hybridization (array-CGH), a genetic diagnosis method, we excluded cases with chromosomal abnormality or large fragment structure variation. Finally, 20 RPL patients and 20 normal pregnant women were enrolled ([Table 1](#t0005){ref-type="table"}). At the time of dilation and curettage, we separated decidua tissues from the products of conception under a dissecting microscope. Firstly, we washed tissue samples thoroughly with sterile normal saline to remove excess blood, mucous and fetal tissues. Then, we transferred fragments of decidua and deciduas with attached chorionic villi to a petri dish with sterile normal saline and examined under a dissecting microscope. The deciduas were carefully dissected out from the branching chorionic villi, flashed frozen in liquid nitrogen and stored at −80 °C for following studies.Table 1Characteristics of subjects.Table 1VariableControl group (*N* = 20)RPL group (N = 20)t*P* valueMateral age (year)[⁎](#tf0005){ref-type="table-fn"}24·333 ± 5·24525·000 ± 2·563−0·3320·744Body mass\
index (BMI) (kg/m^2^) ^⁎^19·962 ± 2·21021·895 ± 3·324−0·8200·423Gestational age (weeks) ^⁎^7·083 ± 1·5677·715 ± 0·572−1·0840·293Pregnant frequency[⁎](#tf0005){ref-type="table-fn"}2·000 ± 1·3481·500 ± 1·0690·8780·391Childbirth frequency[⁎](#tf0005){ref-type="table-fn"}0·583 ± 0·7930·444 ± 0·7271·0680·300NO. of pregnancy loss[⁎](#tf0005){ref-type="table-fn"}--2·63 ± 0·518--[^2][^3]

2.3. DNA isolation and Infinium human methylation 850 K BeadChip {#s0040}
----------------------------------------------------------------

Genome-wide DNA methylation patterns were performed by Infinium Human Methylation 850 K BeadChips (Illumina), which determine the methylation levels of 853,307 CpG sites. After performing bisulfite treatment with EZ DNA Methylation Kit (Zymo Research) following the manufacturer\'s procedure, processed DNA samples were then hybridized to the BeadChip (Illumina) according to the Illumina Infinium HD Methylation Protocol.

Illumina intensity data (IDAT) files from the chip were further processed by the R/Bioconductor (version 3·3·3) package ChAMP. DNA methylation level was reported as β value, ranging from zero to one, where zero represents non-methylated probe and one represents fully methylated probe, for every CpG site. Probes that had a detection *P* value of \>0·01 and those located on the X and Y chromosome were filtered away. We also removed probes with \<three beads in at least 5% of samples per probe, SNP-related probes and all multi-hit probes. BMIQ algorithm was used to correct for the Infinium type I and type II probe bias.

Additionally, we identified differently methylated probes (DMPs) at significance of a Benjamini-Hochberg adjusted *P* \< 0·05 and conducted gene set enrichment analysis to know if genes involved in these significant DMPs are enriched for specific biological terms or pathways. Differentially Methylated Regions (DMRs) were identified by Bumphunter with default settings.

Methylation array data were deposited into Gene Expression Omnibus (GEO) under accession [GSE113600](ncbi-geo:GSE113600){#ir0005}.

2.4. RNA isolation, qRT-PCR and RNA-seq {#s0045}
---------------------------------------

Total RNA from tissues and cells were extracted using TRIzol reagent (Life Technologies). For mRNA detection, 0·5 μg total RNA were reverse transcribed to generate cDNA using the reverse transcription kit (Takara). To measure the expression of mRNA, we employed qRT-PCR on the LightCycler 480 (Roche) along with the GAPDH as the endogenous control. All primers for PCR were listed in Supplementary Table S1. For RNA-seq, libraries were prepared from three biological replicates using the TruSeq RNA Sample Prep Kit and sequenced on the NextSeq (Illumina). After generating read alignments with hg19 by being processed with STAR \[[@bb0120]\], RNA-seq data was then normalized and analyzed using DEseq2 \[[@bb0125]\]. RNA-seq data has been submitted to the GEO repository ([GSE113790](ncbi-geo:GSE113790){#ir0010}).

2.5. Bisulfite sequencing PCR {#s0050}
-----------------------------

Genomic DNA (gDNA) was isolated from the decidua tissue of pregnant women with DNeasy Blood and Tissue kit (Qiagen). 500 ng of gDNA was bisulfite-treated by EZ DNA Methylation Kit (Zymo Research). The sequences of primers used for Bisulfite Sequencing PCR are listed in Supplementary Table S2. Bisulfite-PCR products were amplified by GoTaq Hot Start Polymerase (Promega) according to the manufacturer\'s instructions. The PCR products were purified and ligated into pMD 19-T Vector (Takara). Then, the plasmids were transformed into *E.coli* DH5α Competent Cells (Takara). Sequencing reactions for single amplified clones were performed by Jie Li Biology Co (Shanghai). Sequence data were analyzed by Vector NTI software (Thermo Fisher SCIENTIFIC) and the QUMA website (<http://quma.cdb.riken.jp>/).

2.6. Dual-luciferase reporter assay {#s0055}
-----------------------------------

Functional analysis of *CREB5* DMR was conducted with a dual-luciferase assay. A 1166 bp DNA fragment containing the *CREB5* DMR was amplified by forward primer 5′-GAAGATCTTCTTGCTGGCATCGTTACCT- 3′ and reverse primer 5′-CGGGGTACCGTATTCGACTTCCTCTTTCAACATA-3′. The forward primer contained a *Bgl*II and the reverse primer contained a *Kpn*I recognition site. The PCR product was purified, cloned into pGL3-basic vector and Sanger sequencing was used to check the cloned PCR product. Plasmid DNA was purified by EndoFree Plasmid Kit (QIAGEN). The pGL3-basic vector with *CREB5* DMR insert was *in vitro* methylated by M.SssI (New England Biolabs) and the methylation sensitive enzyme *Hpa*II (New England Biolabs) was used to confirm *in vitro* methylation. Finally, either methylated or unmethylated plasmid was co-transfected with pGL3-SV40 vector (in a ratio of 400:1) in three different cell lines, including HTR8-S/Vneo, JEG-3 and 293 T, using Lipofectamine 2000 (Invitrogen). Luciferase activity in cells was analyzed using the Dual-luciferase Assay System (Promega), luciferase normalized to renilla luciferase activity and the fold increase relative to that of empty pGL3-basic vector as recommended by the manufacturer.

2.7. Chromatin immunoprecipitation (ChIP) {#s0060}
-----------------------------------------

ChIP was performed with the EZ-Magna ChIP A/G Chromatin Immunoprecipitation Kit (Millipore) following the instructions provided by the manufacturer. In brief, solubilized chromatin was sonicated to an average size between 300 and 500 bp and immunoprecipitated with the antibody against IgG (Millipore), P53 (Cell Signaling Technology Cat\# 2527S, RRID:[AB_10695803](nif-antibody:AB_10695803){#ir0020}) and SP1 (Cell Signaling Technology Cat\# 9389S, RRID:[AB_11220235](nif-antibody:AB_11220235){#ir0025}). Antibody--chromatin complexes were pulled-down using magnetic A/G beads, washed and eluted. Purified DNA was quantified with standard qPCR methods using SYBR Green PCR Master Mix (Applied Biosystems) on a 7900HT Fast-Real-Time PCR (ABI) and normalized to values obtained after amplification of unprecipitated (input) DNA. Primer sequences are listed as followed: forward primer 5′- GGGTAAAAGCTTCTGGGGTC- 3′ and reverse primer 5′-CTAGAGGAGAAGGCTTACTGGTGC-3′.

2.8. Western blot {#s0065}
-----------------

Proteins from decidua tissues and cultured cells were extracted using RIPA buffer containing PMSF, and quantified by bicinchoninic acid (BCA) solution (Beyotime, Nantong, China). Protein samples were separated in a 10% SDS-PAGE gel and transferred to PVDF membranes (Millipore). The membrane was blocked with Tris Buffered Saline Tween (TBST), added with 5% non-fat dry milk, and incubated overnight at 4 °C with a primary antibody CREB5 (1:1000, Sigma, St Louis, MO, USA) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH, 1:1000, Beyotime, Nantong, China). After washing three times in TBST buffer, the secondary antibodies anti-mouse or anti-rabbit HRP-linked (Beyotime, Nantong, China) were used at appropriate dilution (1:1000) for 1 h at room temperature. The signals were detected by the addition of Immobilon Western Chemiluminescent HRP Substrate (Millipore).

2.9. Cell culture and transfection {#s0070}
----------------------------------

We obtained human HTR8-S/Vneo cell, JEG-3 cell and 293 T cell from American Type Culture Collection (ATCC). HTR8-S/Vneo cell was cultured in 1640 medium (Gibco), JEG-3 cell was cultured in MEM medium (Gibco) and 293 T cell was cultured in DMEM medium (Gibco), all of which were mixed with 10% fetal bovine serum (FBS) (Gibco), 100 U /ml penicillin (Gibco), and 100 μg/ml streptomycin (Gibco) at 37 °C, 5% CO2. 4 μg of CREB5 overexpression plasmid (pcDNA-CREB5) or negative control (pcDNA-NC) were used in transfection experiments with Lipofectamine 2000 (Invitrogen) following the manufacturer\'s instructions.

2.10. Analysis of CREB5 overexpression and knockdown on cell function {#s0075}
---------------------------------------------------------------------

5\*10^5^ cells transfected with pcDNA-CREB5, pcDNA-NC, si-NC or si-CREB5 about 24 h were incubated in 100 μl serum-free medium inside upper chamber (Millipore) while 600 μl DMEM with 10%FBS were added into the lower chamber. After 24 h, cells were dyed with crystal violet staining solution (Beyotime) and photographed under 20× and 10× magnification. For cell cycle assay, transfected cells were collected and detected by FACS (BD Biasciences). As for cell apoptosis, cells were stained with annexin-V/PI (BD Biopharmingen), and then analyzed by FlowJo V7 software (Tree Star). All experiments were repeated three times independently. CREB5 siRNA were purchased from Gene Pharma (Shanghai, China). The siRNA sequence is as follows: sense: 5′- GCGGAAUAUCUCGAUGCAUTT- 3′, antisense: 5′- AUGCAUCGAGAUAUUCCGCTT- 3′.

2.11. Statistical analyses {#s0080}
--------------------------

Statistical analysis was performed using R software (version 3·3·3). Pearson\'s chi-squared test and Student\'s *t*-test was used to assess statistical differences in demographic and clinical characteristics, including drinking or smoking status, body mass index (BMI), age, abortion frequency and gestational weeks between cases and controls. Each experiment was performed in triplicate and results were considered statistically significant at *P* value \<0·05.

3. Results {#s0085}
==========

3.1. Genome-wide DNA methylation analysis of decidua tissues in RPL and controls {#s0090}
--------------------------------------------------------------------------------

To better understand the role of DNA methylation in RPL, we performed the Infinium Human Methylation 850 K BeadChip arrays in decidua samples from the patients with RPL (*n* = 4) and controls (*n* = 2). The density plot of methylation level between RPL and controls was largely bimodal, indicating that there were no apparent global DNA methylation differences between these two groups (Supplementary Fig. S1a, b). By averaging β-value per Mb in the genome, we described global DNA methylation patterns between RPL and controls using circos plot ([Fig. 1](#f0005){ref-type="fig"}a). The distribution of differentially methylated CpG sites was largely overlapped between these two groups with majority in gene body and intergenic gene regions (IGR) ([Fig. 1](#f0005){ref-type="fig"}b, c). Additionally, differentially methylated probes (DMPs) are evenly distributed on autosomes ([Fig. 1](#f0005){ref-type="fig"}d). Using β-value as DNA methylation level, we identified 107,550 differentially methylated CpG sites between RPL and controls with FDR \< 0·05, among which 45,245 sites showed \>20% β-value difference ([Fig. 1](#f0005){ref-type="fig"}e).Fig. 1DNA methylation patterns in RPL and controls. (a) Circular representation of whole genome DNA methylation level for RPL and controls. CpG methylation level were averaged per Mb in the genome and represent as histograms and heatmaps. (b) Distributions of hyper-methylated and hypo-methylated DMPs were investigated throughout each genomic region, FDR \< 0·05. (c) Genomic locations divided into island, opensea, shelf and shore according to the distance between CpG island and DMPs, FDR \< 0·05. (d) Manhattan plot showing *P* value based on DMPs analyses. The two horizontal lines is the suggestive DNA methylation chip significance threshold cutoff. (e) A volcano plot of the distribution between FDR (adjusted *P* value) and difference in β value (logFC). Lines represent used cutoff values to identify the most hyper-methylated DMPs (red) and hypo-methylated DMPs (green). (f) DNA sequences motifs identified to be enriched in DMRs by CisGenome Browser software. The right column contains the top three transcription factor similar to these motifs using JASPAR database. (g) Gene enrichment analysis of gens with DMPs in RPL.Fig. 1

Given that at CpG island might have stronger function than that single site, we then analyzed differentially methylated regions (DMRs) between RPL and controls. By using the algorithm of Bumphunter, we identified 539 DMRs in autosomal between these two groups including 129 hypo-DMRs and 410 hyper-DMRs (Supplementary Table S3). Functional genomic elements were usually associated with DNA methylation signatures \[[@bb0130]\], thus we hypothesized that RPL-related DMRs may be enriched with transcription factors binding motif. To explore potential transcription factors occupancy in these DMRs, we searched for enriched DNA motifs in DMRs using CisGenome Browser software \[[@bb0135]\], and identified ten new motifs which might regulate the transcription of DMR-related genes through JASPAR database ([Fig. 1](#f0005){ref-type="fig"}f) \[[@bb0140]\]. We next performed gene enrichment analysis using ChAMP to assess whether the DMRs related genes were functionally linked to pregnancy loss. GO analysis indicated an enrichment of genes that are implicated in developmental processes, such us embryonic organ development and branchiomeric skeletal muscle development ([Fig. 1](#f0005){ref-type="fig"}g).

3.2. The correlation of DMRs with genome-wide gene expressions {#s0095}
--------------------------------------------------------------

In order to investigate how DMRs affected the gene transcriptions, we made an unbiased assessment of genome-wide mRNA levels by RNA-seq in decidua samples from the patients with RPL (*n* = 3) and controls (n = 3). With FDR \< 0·05 and fold change\>2, we identified 225 differential expressed genes (DEGs) between RPL and controls (Supplementary Table S4). To verify the RNA-seq results, 20 DEGs were randomly selected and validated in an independent group of RPL and controls. All the results were highly consistent with RNA-seq results (Supplementary Fig. S2a, b). Potential relationships between alterations in DNA methylation and related-genes expression were carried out by comparing the *P* values of DMRs and *P* values of DEGs ([Fig. 2](#f0010){ref-type="fig"}a). By setting a threshold of 5% FDR, we selected four genes, including *CREB5*, *RBM24*, *IRF4*, *DPYSL4*, in the further study. Interestingly, all of these genes had hypo-methylated regions or up-regulated gene expression in RPL. Next, we validated these gene expressions by qRT-PCR and they all significantly higher expressed in RPL group except for *IRF4* ([Fig. 2](#f0010){ref-type="fig"}b).Fig. 2Filtration of genes with synergetic alterations in DNA methylation and gene expression. (a) Quadrant plot showing DMRs and expression of corresponding genes. The dashed lines indicate a threshold of *P* value below 0·05. The blue dots signify hypo-methylated and up-regulated genes in RPL, the brown bots signify hypo-methylated and down-regulated genes in RPL, the purple bots signify hyper-methylated and up-regulated genes in RPL and the red bots signify hyper-methylated and down-regulated genes in RPL. (b) Box plots of relative expression level of four genes selected by a threshold of 5% FDR. Error bars, SEM. \**P* \< 0·05, \*\**P* \< 0·01, \*\*\**P* \< 0·001. Bisulfite sequencing of *CREB5* (c) and RBM24 (d). Open and closed circles represent unmethylated and methylated CpG sites and each row corresponds to a single clone sequenced. All loci shown in picture were found to be hypo-methylated in RPL according to the analysis of Infinium Human Methylation 850 K BeadChip data. (e) The expression of *CREB5* protein in control group and RPL group.Fig. 2

Since the DMRs of *CREB5* and *RBM24* located in the promoters, which might affect gene transcription, bisulfite sequencing was used to determine the DNA methylation in promoter regions of these two genes ([Table 2](#t0010){ref-type="table"}, [Fig. 2](#f0010){ref-type="fig"}c, d). Our results demonstrated that these two genes\' promoters were hypo-methylated in the RPL group compared with the control group. In addition, *CREB5* DMRs in the promoter regions de-methylated more completely than *RBM24*. Then, we chose *CREB5* as a potentially functional gene for further study.Table 2Significant RPL-associated differentially methylated regions (DMRs).Table 2GeneRegionProbesLocation[a](#tf0010){ref-type="table-fn"}β[b](#tf0015){ref-type="table-fn"} (RPL)β[b](#tf0015){ref-type="table-fn"} (Controls)FDR[c](#tf0020){ref-type="table-fn"}CREB5Chr7:28450001-28,451,011cg110935485\'UTR0·070·360·01cg223961475\'UTR0·090·280·001cg14803765TSS15000·080·310·008cg14927519TSS15000·170·330·03cg01332259TSS15000·060·250·003cg17067116TSS15000·040·270·03  RBM24Chr6:17282284--147,282,863cg25302957TSS15000·050·320·002cg026850161stExon0·110·450·01cg15168816TSS15000·130·520·006cg14466942TSS15000·420·700·006cg02066331TSS2000·480·690·02cg02311932TSS2000·380·680·01cg23146346TSS2000·650·910·002cg017290605\'UTR0·660·890·007[^4][^5][^6][^7]

Furthermore, the expression of CREB5 protein was consist with mRNA level by western blot ([Fig. 2](#f0010){ref-type="fig"}e).

3.3. Hypo-DMR of *CREB5* up-regulated its expression by recruiting P53 and SP1 {#s0100}
------------------------------------------------------------------------------

To evaluate the effect of *CREB5* DMR on gene regulation, we cloned the *CREB5* DMR into pGL3-basic luciferase vector. The pGL3-basic vector with methylated or unmethylated insert were co-transfected with an internal control (pGL3-SV40 vector) into the HTR8-S/Vneo cells and JEG-3 cells. Compared to the unmethylated insert vector group, we found that the luciferase activities of methylated insert vectors were significantly decreased in both HTR8-S/Vneo cells and JEG-3 cells (*t* = 5·42, *P* = 5·60\*10^−3^ and *t* = 4·13, *P* = 4·410\*10^−3^, respectively), suggesting that *CREB5* DMR could regulate gene transcription ([Fig. 3](#f0015){ref-type="fig"}a). Given the low transfection efficiency of HTR8-S/Vneo cells and JEG-3 cells, we repeated the report assay in 293 T cells, and the results were consistent with the above two cell lines (*t* = 13·54, *P* = 1·72\*10^−4^) ([Fig. 3](#f0015){ref-type="fig"}a).Fig. 3*CREB5* DMR regulates gene expression through recruiting P53 and SP1. (a) The pGL3-basic vector with methylated or unmethylated *CREB5* DMR were co-transfected with pGL3-SV40 vector (negative control) in three different cell lines, HTR8-S/Vneo cell, JEG-3 cell and 293 T cell. Firefly/Renilla ratio was normalized to the empty vector. (b) ChIP-qPCR showing P53 enrichment over *CREB5* DMR in HTR8-S/Vneo cells. (c) ChIP-qPCR showing SP1 enrichment over *CREB5* DMR in HTR8-S/Vneo cells. \*\**P* \< 0·01, \*\*\**P* \< 0·001. All histograms represent mean ± SEM.Fig. 3

To uncover *CREB5* DMR\'s regulatory mechanisms on gene expression, PROMO was used to search the transcription factor consensus binding motifs within DMR, and P53 and SP1 binding sites were enriched and contained cg14927519 \[[@bb0145]\]. ChIP-qPCR was used to validate the P53 and SP1 binding in *CREB5* DMR. In *CREB5* overexpression cells, both P53 and SP1 were enriched in *CREB5* DMR, indicating that P53 and SP1 might be recruited to hypo-DMR andup-regulated CREB5 ([Fig. 3](#f0015){ref-type="fig"}b, c).

3.4. Effects of *CREB5* overexpression on cell function {#s0105}
-------------------------------------------------------

In an attempt to assure whether up-regulated *CREB5* affects cell function, we overexpressed *CREB5* in HTR8-S/Vneo and JEG-3 cell lines ([Fig. 4](#f0020){ref-type="fig"}a and [Fig. 5](#f0025){ref-type="fig"}a). Next, we assessed the effects of *CREB5* overexpression on cell migration, and the number of migrated cells were significantly induced after overexpression of *CREB5* (Fig. 4band [Fig. 5](#f0025){ref-type="fig"}b). Besides, by flow cytometer assays, we observed that cell apoptosis was significantly increased in HTR8-S/Vneo cells (*t* = 4·39, *P* = 1·18\*10^−2^) ([Fig. 4](#f0020){ref-type="fig"}c, d) and JEG-3 cells (t = 4·87, *P* = 8·19\*10^−3^) ([Fig. 5](#f0025){ref-type="fig"}c, d). In addition, *CREB5* overexpression had effects on cell cycle with significantly increased S phase cells (*t* = 2·49, *P* = 2·83\*10^−2^) and induced G2/M phase cells (t = 2·37, *P* = 3·51\*10^−2^) in HTR8-S/Vneo cells ([Fig. 4](#f0020){ref-type="fig"}f, g), revealing that *CREB5* blocked the cells in the S phase, similar results were also observed in JEG-3 cells ([Fig. 5](#f0025){ref-type="fig"}f, g).Fig. 4Functional analysis of *CREB5* overexpression in HTR8-S/Vneo cells. (a) Evaluation of the mRNA and protein level of *CREB5* after transfection. (b) Transwell analysis of HTR8-S/Vneo cells transfected *CREB5* overexpression plasmid and empty plasmid (negative control). Scale bars; 500 μm. (c and d) Assessment of cell apoptosis was detected by flow cytometer. (e and f) Analysis of the effects of *CREB5* overexpression on cell cycle by flow cytometer. The data are presented as mean ± SEM. \**P* \< 0·05, \*\**P* \< 0·01, \*\*\**P* \< 0·001.Fig. 4Fig. 5Functional analysis of *CREB5* overexpression in JEG-3 cells. (a) qRT-PCR and western blot was used to detect the expression level of *CREB5* mRNA and protein *CREB5*after transfection. (b) Transwell assay showed that *CREB5* overexpression delayed cell migration. Scale bars; 500 μm. (c and d) The result of cell apoptosis indicated that *CREB5* overexpression increased significantly the percentage of apoptotic cells. (e and f) Cell counts showed *CREB5* overexpression increased significantly S-phase cells and reduced significantly G2/M-phase cells. The data are presented as mean ± SEM. \**P* \< 0·05, \*\**P* \< 0·01, \*\*\**P* \< 0·001.Fig. 5

To further understand the function of *CREB5*, we knocked down *CREB5* in HTR8-S/Vneo and JEG-3 cell lines ([Fig. 6](#f0030){ref-type="fig"}a). As shown in [Fig. 6](#f0030){ref-type="fig"}, cell migration was markedly increased after transfection of *CREB5* siRNA both in HTR8-S/Vneo and JEG-3 cell lines ([Fig. 6](#f0030){ref-type="fig"}b). However, no significant difference of cell apoptosis was found in HTR8-S/Vneo and JEG-3 cells ([Fig. 6](#f0030){ref-type="fig"}c and d). Besides, *CREB5* knockdown affected cell cycle both in HTR8-S/Vneo and JEG-3 cells ([Fig. 6](#f0030){ref-type="fig"}e and f), indicating that *CREB5* delayed cell progression in G1 to S transition.Fig. 6Functional analysis of *CREB5* knockdown in HTR8-S/Vneo and JEG-3 cell lines. (a) The expression level of *CREB5* protein after transfection. (b) Transwell analysis of HTR8-S/Vneo and JEG-3 cells transfected *CREB5* siRNA and negative control. Scale bars; 100 μm. (c and d) The result of cell apoptosis HTR8-S/Vneo and JEG-3 cells. (e and f) Analysis of the effects of *CREB5* overexpression on cell cycle by flow cytometer. The data are presented as mean ± SEM. \**P* \< 0·05, \*\**P* \< 0·01.Fig. 6

4. Discussion {#s0110}
=============

RPL, the commonest complication of pregnancy, affecting about 1% of couples \[[@bb0150]\]. Several pregnancy complications like pre-eclampsia and intrauterine growth restriction (IUGR) are caused by defects in decidualization of the endometrium during early pregnancy, which is considered to be important in the pathogenesis of RPL. In order to explore the potential mechanism of DNA methylation involved in RPL, we carried out combined analysis of DNA methylation and gene expression, and identified *CREB5* as contributor to RPL.

In current study, we performed 850 K assays to analyze the differential methylation of about 853,307 CpGs throughout the whole genome and used strict statistical criteria to define differential methylated sites between RPL and controls. Interestingly, we observed subtle concordant changes rather than all-or-none methylation changes in multiple CpGs distributed at specific gene loci. To further investigate the influence of DNA methylation on transcriptional regulation, we employed RNA-seq and found a set of genes that were hypo-methylated and up-regulated in RPL, including *CERB5*, *RBM24*, *DPYSL4* and *IRF4*. Considering the levels of DMRs methylation and gene expressions, we finally selected *CREB5* as a candidate gene for further study.

Transcriptome analysis showed that dysregulation of genes associated with cell invasion and immunity might contribute to idiopathic RPL \[[@bb0155]\]. *CREB5* gene, belonging to the CRE (cAMP response element)-binding protein family, has crucial roles in regulating cell growth, proliferation, differentiation and cell cycle \[[@bb0160], [@bb0165]\]. Recently, relevant studies have suggested that the up-regulation of *CREB5* is negatively correlated with the prognosis of epithelial ovarian cancer and non-small cell lung cancer and accelerate the metastasis of cancers \[[@bb0165], [@bb0170]\]. In addition, modifications of *CREB5* methylation and expression were reported to be associated with plasma interleukin-6 (IL-6) levels and map to the network of inflammatory response genes \[[@bb0175]\]. Notably, knockdown *CREB5* in monocytes could increase tumor necrosis factor alpha (TNF-α) level, decrease interleukin-10 (IL-10) level in cell-free plasma and enhance expression of phosphorylated--NF-κB p65 and NF-κBp65, thus causing immunosuppression \[[@bb0180]\]. Moreover, several investigations suggested the functions of *CREB* in immune responses, including macrophage survival, regulation of T and B lymphocytes and inducing transcription of immune-related genes, for example, IL-10 \[[@bb0185]\]. Thus, we speculate that *CREB5* hypo-methylation may contribute to pregnancy immunity regulation and upregulation of *CREB5* in the decidua tissue may be associated with the occurrence of RPL. However, the discussion is speculative because we do not demonstrate in which cell type *CREB5* is expressed or deregulated at the feto-maternal interface.

DNA hypo-methylation, particularly in promoter and enhancer regions, is often accompanied with increased binding of transcription factors \[[@bb0190]\]. We found p53 and SP1 might bind to DMR near *CREB5*, which were validated by ChIP-qPCR. SP1 is a widely expressed transcription factor and plays critical roles in transcriptional regulation by binding to GC-rich cis-elements in many promoter regions \[[@bb0195]\]. SP1 can also interact with other transcription factors like methyl transferases, acetylases/de-acetylases, and other chromatin modifying molecules, which are involved in numerous cellular processes including cell growth, apoptosis, immune responses and so on \[[@bb0200]\]. P53, a transcription factor and tumor suppressor, plays a vital role in the cell cycle and functions as an important signaling hub for the cellular response to various stresses \[[@bb0205], [@bb0210]\]. Both of SP1 and P53 have effects on cell function, which are consist with our functional analysis of *CREB5* overexpression. These findings support our speculation that hypo-DMR near *CREB5* could up-regulate *CREB5* gene expression by recruiting P53 and SP1, thus increasing cell migration and cell apoptosis, blocking cell cycle and eventually resulting in RPL by causing immune abnormalities.

In conclusion, in this study, we found a set of genes relevant to RPL by integrating analysis of DNA methylation and gene expression. Hypo methylation of *CREB5* could recruit P53 and SP1 binding to *CREB5* DMR and upregulate *CREB5* in turn, which altered trophoblast cell functions. Our results highlight that *CREB5* may play a critical role in the pathogenesis of RPL.
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